Shareholder lawsuits filed against Spectrum based on stock drop tied to Fusilev sales
This article was originally published in Scrip
Executive Summary
It seemed inevitable when Spectrum Pharmaceuticals announced that 2013 Fusilev (levoleucovorin) revenue would be less than half of 2012 sales that shareholders would file lawsuits related to the drastic decline in the company's stock price.